Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors-Reference-Cited by-同舟云学术

Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors

Published:2017-07-31 Issue:18 Volume:77 Page:5107-5117
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Chen Weicai,Kuang Ye,Qiu Hai-Bo,Cao Zhifa,Tu Yuqing,Sheng Qing,Eilers Grant,He Quan,Li Hai-Long,Zhu Meijun,Wang Yuexiang,Zhang Rongqing,Wu Yeqing,Meng Fanguo,Fletcher Jonathan A.,Ou Wen-Bin

Funder

Major Science and Technology

Science Foundation of Zhejiang Sci-Tech University

Zhejiang Sci-Tech University

National Natural Science Foundation of China

Natural Science Foundation of Zhejiang Province

NIH

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST;Cell Communication and Signaling;2024-02-27

2. Targeting BCL6 in Gastrointestinal Stromal Tumor Promotes p53-Mediated Apoptosis to Enhance the Antitumor Activity of Imatinib;Cancer Research;2023-08-09

3. SETDB1 tumour suppressor roles in near-haploid mesothelioma involve TP53;British Journal of Cancer;2023-06-27

4. Co-targeting of ACK1 and KIT triggers additive anti-proliferative and -migration effects in imatinib-resistant gastrointestinal stromal tumors;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2023-06

5. Advances in Drug Therapy for Gastrointestinal Stromal Tumour;Current Medicinal Chemistry;2023-05-05